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Genetic Predisposition to High Blood Pressure Associates
With Cardiovascular Complications Among Patients With
Type 2 Diabetes
Two Independent Studies
Qibin Qi,1 John P. Forman,2 Majken K. Jensen,1 Alan Flint,1 Gary C. Curhan,2,3 Eric B. Rimm,1,2,3
Frank B. Hu,1,2,3 and Lu Qi1,2
Hypertension and type 2 diabetes (T2D) commonly coexist, and
both conditions are major risk factors for cardiovascular disease
(CVD). We aimed to examine the association between genetic pre-
disposition to high blood pressure and risk of CVD in individuals
with T2D. The current study included 1,005 men and 1,299 women
with T2D from the Health Professionals Follow-up Study and
Nurses’ Health Study, of whom 732 developed CVD. A genetic
predisposition score was calculated on the basis of 29 established
blood pressure–associated variants. The genetic predisposition
score showed consistent associations with risk of CVD in men
and women. In the combined results, each additional blood
pressure–increasing allele was associated with a 6% increased risk
of CVD (odds ratio [OR] 1.06 [95% CI 1.03–1.10]). The OR was 1.62
(1.22–2.14) for risk of CVD comparing the extreme quartiles of the
genetic predisposition score. The genetic association for CVD risk
was signiﬁcantly stronger in patients with T2D than that estimated
in the general populations by a meta-analysis (OR per SD of ge-
netic score 1.22 [95% CI 1.10–1.35] vs. 1.10 [1.08–1.12]; I2 = 71%).
Our data indicate that genetic predisposition to high blood pres-
sure is associated with an increased risk of CVD in individuals with
T2D. Diabetes 61:3026–3032, 2012
Patients with type 2 diabetes (T2D) have a two- tofourfold higher risk of developing cardiovasculardisease (CVD) than nondiabetic people (1). Manyconditions that coexist with T2D, such as high
blood pressure, also contribute to CVD risk (2). It has been
suggested that up to 75% of CVD in patients with diabetes
may be attributable to high blood pressure (2–4). Blood
pressure is a heritable trait inﬂuenced by multiple genetic
factors (5). Recently, 29 independent genetic variants were
indentiﬁed as associated with systolic and/or diastolic
blood pressure by the International Consortium for Blood
Pressure genome-wide association studies (GWAS) with
a multistage design in ;200,000 individuals of European
descent (5). A genetic risk score based on these 29 genetic
variants was also reported to be associated with hyper-
tension and CVD risk in general populations (5). We and
others have shown that diabetes-related metabolic
derangements may modify genetic effects on CVD risk
(6,7). However, whether the effects of blood pressure–
associated variants on CVD risk differ in patients with T2D
is unknown. In addition, many dietary and lifestyle risk
factors for hypertension have been identiﬁed (8), such as
BMI, physical activity, the Dietary Approach to Stop Hy-
pertension (DASH) diet, alcohol intake, use of nonnarcotic
analgesics, and supplemental folic acid intake. It is unknown
whether these dietary and lifestyle risk factors inﬂuence the
association between the high blood pressure–predisposing
variants and CVD risk.
Therefore, we constructed a genetic predisposition
score on the basis of 29 high blood pressure–predisposing
variants and examined the association between the genetic
predisposition score and risk of CVD among men and
women with T2D from the Health Professionals Follow-up
Study (HPFS) and Nurses’ Health Study (NHS). We also
compared our ﬁndings in patients with T2D with those in
the general population, assessed by meta-analysis.
RESEARCH DESIGN AND METHODS
The HPFS is a prospective cohort study of 51,529 U.S. male health professionals
who were 40–75 years of age at study inception in 1986 (9). Between 1993 and
1999, 18,159 men provided blood samples. The NHS is a prospective cohort
study of 121,700 female registered nurses who were 30–55 years of age at
study inception in 1976 (10). A total of 32,826 women provided blood samples
between 1989 and 1990. In the current analysis for the NHS, 1980 was deﬁned
as the baseline year because diet was ﬁrst assessed since that year. In both
cohorts, information about medical history, lifestyle, and disease has been
collected biennially by self-administered questionnaires.
For the current study, NHS and HPFS participants were T2D case subjects
who had genotype data from the NHS and HPFS T2D GWAS (11). T2D case
subjects were deﬁned according to self-reported T2D conﬁrmed by a validated
supplementary questionnaire. For case subjects before 1998, we used the Na-
tional Diabetes Data Group criteria to deﬁne T2D (12), which included one of
the following: one or more classic symptoms (excessive thirst, polyuria, weight
loss, hunger, pruritus, or coma) plus fasting plasma glucose level of $7.8 mmol/L
(140 mg/dL), random plasma glucose level of $11.1 mmol/L (200 mg/dL), or
plasma glucose level 2 h after an oral glucose tolerance test of $11.1 mmol/L
(200 mg/dL); at least two elevated plasma glucose levels (as described pre-
viously) on different occasions in the absence of symptoms; or treatment with
hypoglycemic medication (insulin or oral hypoglycemic agent). The validity of
this method has been conﬁrmed (13). We used the American Diabetes Asso-
ciation diagnostic criteria for diabetes diagnosis from 1998 onward (14). These
criteria were the same as those proposed by the National Diabetes Data Group
except for the elevated fasting plasma glucose criterion, for which the cut
point was changed from 7.8 mmol/L (140 mg/dL) to 7.0 mmol/L (126 mg/dL).
CVD cases were deﬁned as coronary heart disease (CHD) (fatal or nonfatal
myocardial infarction, coronary artery bypass grafting, or percutaneous
transluminal coronary angioplasty) or stroke (fatal or nonfatal). Nonfatal
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myocardial infarction was conﬁrmed by review of medical records using the
criteria of the World Health Organization of symptoms plus either typical elec-
trocardiographic changes or elevated levels of cardiac enzymes. Nonfatal stroke
was conﬁrmed by review of medical records using the criteria of the National
Survey of Stroke (15). Fatal myocardial infarction and fatal stroke were
conﬁrmed by review of medical records or autopsy reports with the permission
of the next of kin. Physicians blinded to risk factor status reviewed the medical
records. Only diabetic patients who were diagnosed with CVD after the
diagnosis of T2D through 2008 were included as cardiovascular complication
case subjects. Control subjects were deﬁned as those free of CVD after the di-
agnosis of T2D through 2008. Finally, a total of 1,005 men and 1,299 women with
T2D of European ancestry were included: 380 men (351 CHD and 29 stroke) and
347 women (292 CHD and 55 stroke) with cardiovascular complications, and
1,572 (625 men and 947 women) non-CVD control subjects. The study was
approved by the Human Research Committee at the Brigham and Women’s
Hospital, and all participants provided written informed consent.
Genotyping and imputation. DNA was extracted from the buffy coat fraction
of centrifuged blood using a commercially available kit (QIAmp Blood kit;
Qiagen, Chatsworth, CA). We selected 29 single nucleotide polymorphisms
(SNPs) associated with systolic and/or diastolic blood pressure at a genome-
wide signiﬁcance level (Supplementary Table 1) (5). SNP genotyping and
imputation have previously been described in detail (11). Brieﬂy, samples
were genotyped and analyzed using the Affymetrix Genome-Wide Human 6.0
array (Affymetrix; Santa Clara, CA) and the Birdseed calling algorithm. We
used MACH (http://www.sph.umich.edu/csg/abecasis/MACH) to impute SNPs
on chromosomes 1–22 with National Center for Biotechnology Information
build 36 of Phase II HapMap CEU data (release 22) as the reference panel.
Most of the SNPs included in the genetic predisposition score were directly
genotyped (12 SNPs) or had a high imputation quality score (15 SNPs, MACH
r2 $ 0.8), and 2 SNPs showed a moderate imputation quality score
(rs13107325, r2 = 0.67 [HPFS] and 0.69 [NHS]; rs2521501, r2 = 0.60 [both NHS
and HPFS]) (Supplementary Table 1).
Genetic predisposition score calculation. Genetic predisposition score was
calculated on the basis of the 29 SNPs by the previously reported weighted
method (5,16). Each SNP was weighted by the average effect size
(b-coefﬁcient) for systolic and diastolic blood pressure obtained from the
reported GWAS (5). The genetic predisposition score was calculated by mul-
tiplying each b-coefﬁcient by the number of corresponding risk alleles and
then summing the products. Because this produced a score out of 26.425
(twice the sum of the b-coefﬁcients), the values were divided by 26.425 and
multiplied by 58 (the total number of the risk alleles) to make the genetic
predisposition score easier to interpret. Each point of the genetic pre-
disposition score corresponded to each blood pressure–increasing allele.
Assessment of dietary and lifestyle factors. Information about anthropo-
metric data, smoking status, physical activity, menopausal status, and post-
menopausal hormone therapy (women only); family history of myocardial
infarction; and medical and disease history was derived from the baseline
questionnaires (9,10). Participants were asked to report whether a clinician had
made a diagnosis of hypertension during the preceding 2 years and were also
asked whether they had undergone a physical examination or screening ex-
amination. Self-reported hypertension was shown to be highly reliable in the
NHS and HPFS (17,18). In a subset of women who reported hypertension,
medical record review conﬁrmed a documented systolic and diastolic blood
pressure .140 and 90 mmHg, respectively, in 100% and .160 and 95 mmHg in
77%; additionally, self-reported hypertension was predictive of subsequent
cardiovascular events (17). BMI was calculated as weight in kilograms divided
by the square of height in meters. For men, physical activity was expressed as
METs per week by using the reported time spent on various activities, weighting
each activity by its intensity level. For women, physical activity was expressed
as hours per week because MET task hours were not measured at baseline in
the NHS. The validity of the self-reported body weight and physical activity data
has previously been described (19–21). Use of nonnarcotic analgesics (use of
aspirin in the NHS and use of aspirin and acetaminophen in the HPFS) was
reported on the baseline questionnaires. Alcohol intake and other detailed di-
etary information was collected from semiquantitative food-frequency ques-
tionnaires at baseline. The reproducibility and validity of the food-frequency
questionnaires have previously been reported (22,23). Based on the diet pre-
scribed in the DASH trial (24), a DASH score was constructed based on high
intake of fruits, vegetables, nuts and legumes, low-fat dairy products, and whole
grains and low intake of sodium, sweetened beverages, and red and processed
meats (25). The intake of supplemental folic acid in multivitamins or in isolated
form was determined by the brand, type, and frequency of reported use.
Statistical analyses. x2 tests and t tests were used for comparison of
proportions and means of baseline characteristics between CVD case and
control subjects. We used logistic regression to estimate odd ratios (ORs) and
95% CIs for CVD risk, adjusting for age and BMI. In multivariable analysis, we
further adjusted for family history of myocardial infarction (yes or no), smoking
(never, past, or current), menopausal status (pre- or postmenopausal [never,
past, or current hormone use] [women only]), physical activity (quartiles),
alcohol intake (0, 0.1–4.9, 5.0–9.9 10.0–14.9 or $ 15.0 g/day), DASH diet score
(quartiles), nonnarcotic analgesics use (yes or no), and supplemental folic acid
use (yes or no). Results in women and men were pooled by using inverse
variance weights under a ﬁxed model, as there was no heterogeneity. Linear
relation analysis between the genetic predisposition score (as continuous
variables) and risk of CVD was performed by using a restricted cubic spline
regression model (26). In secondary analyses, we tested whether the association
between the genetic predisposition score and risk of CVD was modiﬁed by self-
reported hypertension status, BMI, physical activity, DASH diet score, alcohol
intake, use of nonnarcotic analgesic, and use of supplemental folic acid using
analyses stratiﬁed by these factors and by including the respective interaction
terms in the models. Similar analyses were repeated for the association between
the genetic predisposition score and CHD risk. In addition, we performed
a meta-analysis to compare the result in patients with T2D with that in general
populations (i.e., participant groups not restricted to patients with diabetes). All
reported P values are nominal and two side. Statistical analyses were performed
in STATA version 10.0 (StataCorp, College Station, TX) or SAS 9.1 (SAS
Institute, Cary, NC).
RESULTS
Characteristics of study participants. Table 1 shows
the characteristics of study participants. Among diabetic
men and women, CVD case subjects were older, had
TABLE 1
Baseline characteristics among 1,005 men and 1,299 women with T2D
Variables
Men Women
Control subjects CVD case subjects Control subjects CVD case subjects
N 625 380 947 352
Age (years) 54 6 8 58 6 8 46 6 7 50 6 6
BMI (kg/m2) 27.6 6 4.0 28.1 6 4.3 28.1 6 5.1 29.7 6 5.8
Family history of myocardial infarction 34.1 40.5 23.7 31.0
Current smokers 11.6 11.1 22.9 29.3
Hypertension 25.4 45.8 10.8 16.8
Alcohol (g/day) 11.4 6 15.4 10.3 6 16.2 4.8 6 9.5 3.8 6 8.7
Physical activity* 14.8 6 18.7 14.9 6 20.1 3.9 6 2.8 3.3 6 2.6
DASH score 23.4 6 5.2 24.3 6 5.2 23.6 6 4.4 24.0 6 4.4
Supplemental folic acid intake (mg/day) 105 6 203 139 6 245 90 6 193 108 6 189
Use of nonnarcotic analgesics 36.8 43.4 43.0 50.8
Postmenopausal — — 44.1 69.9
Genetic predisposition score 30.7 6 3.2 31.3 6 3.2 30.9 6 3.3 31.3 6 3.1
Data are means 6 SD or % unless otherwise indicated. *MET task hours per week for men and hours per week for women.
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higher BMI, consumed less alcohol, and were more likely
to have a family history of myocardial infarction, have self-
reported hypertension, and use nonnarcotic analgesics
than non-CVD control subjects.
The genetic predisposition score ranged from 18.1 to
40.8, and the mean 6 SD was 31.0 6 3.2 in both women
and men. After adjustment for age and BMI, the genetic
predisposition score was signiﬁcantly associated with self-
reported hypertension in both men and women. The ORs
associated with each additional point of the score, which
corresponds to one additional blood pressure–increasing
allele, were 1.09 (95% CI 1.05–1.14) in men and 1.05 (1.01–
1.09) in women.
Genetic predisposition score and CVD risk. As shown
in Table 2, the ORs for CVD risk were 1.06 (95% CI 1.02–
1.10) and 1.05 (1.01–1.09) with each additional point of the
genetic predisposition score in diabetic men and women,
respectively, adjusted for age and BMI. Multivariable
adjustment did not change the associations. With no
sex differences in ORs (all P for heterogeneity .0.26), we
combined the results from men and women by using meta-
analysis under a ﬁxed-effects model. Each additional point
of the genetic predisposition score was associated with
a 6% increased risk of developing CVD (OR 1.06 [95% CI
1.03–1.10]), adjusted for age, BMI, and other dietary and
lifestyle risk factors. The ORs for CVD risk signiﬁcantly
increased across the quartiles of the genetic predisposition
score (P for trend = 0.0001). Compared with those in the
lowest quartile, participants in the highest quartile of the
genetic predisposition score had an OR of 1.62 (95% CI
1.22–2.14), adjusted for age, BMI, and other dietary and
lifestyle risk factors. The association was attenuated but
remained signiﬁcant after further adjustment for self-
reported hypertension (P for trend = 0.002). We further
examined the association between the genetic pre-
disposition score and CVD risk stratiﬁed by baseline hy-
pertension status (Table 3). Although the association was
more pronounced in patients with hypertension than in
those without hypertension, there was no signiﬁcant
interaction (P for interaction = 0.19). In addition, we
also used a restricted cubic spline regression model to
investigate the association continuously (Fig. 1). The ge-
netic predisposition score showed a linear relationship
with increasing risk of CVD (P for linearity = 0.002, 0.028,
and 0.0001 in men, women, and men and women com-
bined, respectively).
Results were similar when the outcome was restricted to
CHD. The ORs for CHD risk per blood pressure–increasing
allele were 1.07 (95% CI 1.02–1.12) and 1.05 (1.00–1.10) in
diabetic men and women, respectively, adjusted for age,
BMI, and other dietary and lifestyle risk factors. In the
combined results of men and women, the multivariable-
adjusted OR was 1.55 (1.16–2.07) for CHD risk by com-
paring extreme quartiles of the genetic predisposition
score (P for trend = 0.0002). Restricted cubic spline re-
gression analysis also showed that there was a linear re-
lationship between the genetic predisposition score and
CHD risk (P for linearity = 0.0007).
Stratiﬁed analyses by dietary and lifestyle risk
factors. We next examined whether the association be-
tween the genetic predisposition to high blood pressure
and CVD risk varied across subgroups of the population
stratiﬁed by dietary and lifestyle risk factors for hyper-
tension. In combined results from men and women, we
observed consistent associations across subgroups of the
population stratiﬁed by BMI, physical activity, DASH diet
score, alcohol intake, nonnarcotic analgesics use, and
supplemental folic acid use (Table 3). There was no sig-
niﬁcant interaction between the genetic predisposition
score and these dietary and lifestyle risk factors (all P for
interaction .0.39). Results were similar in both sexes
when we performed analyses in men and women sepa-
rately (data not shown).
Genetic effects in patients with diabetes compared
with general populations.We then compared our results
in patients with T2D with data in general populations (i.e.,
participant groups that were not restricted to patients with
diabetes) (Fig. 2). We used ﬁxed-effects meta-analysis to
combine the risk ratios for CVD (stroke or CHD) pre-
viously reported in such populations (5) and the risk ratios
derived from a GWAS of CHD performed in nondiabetic
participants of HPFS and NHS (Supplementary Data) (27).
TABLE 2




P for trendQuartile 1 Quartile 2 Quartile 3 Quartile 4
Men
N (case/control subjects) 67/157 87/155 108/157 118/156
Score median (range) 27.0 (20.0–28.5) 29.7 (28.6–30.7) 31.8 (30.8–32.7) 34.2 (32.8–39.6)
OR (95% CI)
Age and BMI adjusted 1.06 (1.02–1.10) 1.00 1.32 (0.88–1.97) 1.61 (1.09–2.37) 1.74 (1.18–2.55) 0.003
Multivariate adjusted* 1.07 (1.02–1.11) 1.00 1.32 (0.88–1.99) 1.65 (1.11–2.46) 1.72 (1.17–2.55) 0.004
Women
N (case/control subjects) 75/236 82/238 101/236 94/237
Score median (range) 27.2 (18.2–28.5) 29.8 (28.6–30.9) 31.9 (31.0–33.2) 34.9 (33.3–40.8)
OR (95% CI)
Age and BMI adjusted 1.05 (1.01–1.09) 1.00 1.02 (0.70–1.49) 1.50 (1.03–2.17) 1.37 (0.94–1.98) 0.03
Multivariate adjusted* 1.06 (1.01–1.11) 1.00 0.95 (0.62–1.44) 1.45 (0.97–2.19) 1.50 (1.00–2.26) 0.01
Combined OR (95% CI)†
Age and BMI adjusted 1.05 (1.02–1.08) 1.00 1.15 (0.87–1.52) 1.55 (1.18–2.03) 1.53 (1.17–2.00) 0.0002
Multivariate adjusted* 1.06 (1.03–1.10) 1.00 1.12 (0.84–1.51) 1.55 (1.17–2.07) 1.62 (1.22–2.14) 0.0001
*Adjusted for age, BMI, family history of myocardial infarction, smoking, menopausal status (women only), physical activity, alcohol intake,
DASH diet score, nonnarcotic analgesics use, and supplemental folic acid use. †Results were combined between women and men using
inverse variance weights under a ﬁxed model, as there was no heterogeneity between women and men (all P for heterogeneity .0.26).
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The risk ratios per SD of the genetic predisposition score
were approximately 1.1 among these studies, with a com-
bined risk ratio of 1.10 (95% CI 1.08–1.12) and no hetero-
geneity (I2 = 0%). We recalculated the CVD risk per SD of
the genetic predisposition score in our T2D patients and
observed a stronger effect of the genetic predisposition
score on CVD risk (OR 1.22 [95% CI 1.10–1.35]) compared
with that in the general populations. The associations be-
tween the genetic predisposition score and CVD risk
showed signiﬁcant heterogeneity between the diabetic and
the general populations (I2 = 71%, P for heterogeneity =
0.045).
DISCUSSION
In two independent studies of men and women with T2D,
we examined the association between a genetic pre-
disposition score, composed of 29 independent high blood
pressure–predisposing variants, and risk of CVD. Our
highly consistent results in men and women indicate that
the genetic predisposition to high blood pressure may
signiﬁcantly increase risk of cardiovascular complications
in diabetic patients, independent of dietary and lifestyle
risk factors for hypertension.
Because each individual SNP may have a moderate ge-
netic effect and only explain a small proportion of the
variation of blood pressure, we examined the collective
contribution of the multiple genetic variants by computing
a genetic predisposition score, which emphasized the
overall genetic susceptibility to high blood pressure. As
greater genetic variance was explained by multiple var-
iants, the genetic predisposition might be estimated more
accurately by using this approach. In diabetic patients,
each additional blood pressure–increasing allele in the
genetic predisposition score was associated with a 6% in-
creased risk of CVD. By accumulation, individuals in the
highest quartile of the score had a 60% greater risk of de-
veloping CVD than those in the lowest quartile. Therefore,
this approach provides a broader characterization of the
individual’s genetic risk proﬁle, which may be useful for
identifying a substantial proportion of people with a high
genetic risk of CVD.
High blood pressure is one of the most important risk
factors for CVD risk in patients with T2D (2–4). That the
observed genetic associations should be unaffected by
confounding from environmental factors and free of re-
verse causation (28) suggests that there is a casual re-
lationship between the genetic predisposition to high
blood pressure and increased risk of CVD. This is in line
with the fact that hypertension plays a casual role in the
development of CVD, which has been supported by several
controlled clinical trials indicating that control of blood
pressure signiﬁcantly reduces the cardiovascular compli-
cations in patients with T2D (29–35), although it remains
debatable whether tight control of blood pressure offers
additional beneﬁts in the reduction of cardiovascular risk
compared with usual control of blood pressure (35–37).
One of our novel ﬁndings is that the association between
the high blood pressure genetic predisposition score and
risk of CVD was signiﬁcantly stronger in patients with T2D
TABLE 3






for trendQuartile 1 Quartile 2 Quartile 3 Quartile 4
Self-reported hypertension
No 499/1,311 1.00 1.15 (0.85–1.57) 1.37 (1.01–1.85) 1.28 (0.95–1.74) 0.06
Yes 233/261 1.00 1.02 (0.56–1.87) 1.86 (1.03–3.37) 1.84 (1.03–3.26) 0.007
P for interaction 0.19
BMI
,25 kg/m2 172/426 1.00 1.10 (0.62–1.98) 1.63 (0.92–2.86) 1.36 (0.77–2.39) 0.16
$25 kg/m2 560/1,146 1.00 1.15 (0.84–1.57) 1.50 (1.11–2.02) 1.55 (1.15–2.09) 0.001
P for interaction 0.39
Physical activity (by sex-speciﬁc median)
High 286/618 1.00 1.47 (0.93–2.30) 1.57 (1.01–2.43) 1.87 (1.20–2.91) 0.007
Low 382/797 1.00 0.94 (0.65–1.36) 1.39 (0.97–1.99) 1.32 (0.92–1.87) 0.04
P for interaction 0.92
DASH diet score (by sex-speciﬁc median)
High 382/736 1.00 1.45 (0.97–2.14) 1.79 (1.23–2.60) 1.65 (1.14–2.41) 0.006
Low 307/739 1.00 0.93 (0.62–1.40) 1.30 (0.87–1.95) 1.41 (0.94–2.09) 0.03
P for interaction 0.83
Alcohol intake
Modest (0.1–9.9 g/day) 270/914 1.00 1.39 (0.90–2.16) 1.45 (0.94–2.25) 1.75 (1.13–2.71) 0.01
Other (none or $10.0 g/day) 419/857 1.00 1.03 (0.71–1.49) 1.58 (1.11–2.25) 1.40 (0.99–1.99) 0.02
P for interaction 0.90
Nonnarcotic analgesics use
No 326/590 1.00 1.04 (0.68–1.58) 1.43 (0.94–2.16) 1.51 (1.00–2.27) 0.02
Yes 371/872 1.00 1.31 (0.89–1.91) 1.64 (1.14–2.37) 1.67 (1.16–2.42) 0.003
P for interaction 0.79
Supplemental folic acid use
Yes 219/395 1.00 1.01 (0.59–1.73) 1.63 (0.98–2.71) 1.57 (0.94–2.62) 0.02
No 470/1,080 1.00 1.24 (0.89–1.73) 1.48 (1.06–2.05) 1.50 (1.09–2.08) 0.009
P for interaction 0.56
Data are OR (95% CI) unless otherwise indicated. Results are based on pooled data from men and women, adjusted for age and sex.
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than that previously reported in various general pop-
ulations (5). In the general population, each additional SD
of the genetic predisposition score may increase CVD risk
by ;10%, while the increment of CVD risk per SD of the
genetic predisposition score was 22% in patients with T2D.
This ﬁnding is consistent with some previous data from
clinical trials in which blood pressure–lowering reduced
the rate of CVD events more in patients with T2D than in
those without diabetes (31,33). Given a comparable
amount in reduction of systolic blood pressure, the risk
reduction in CVD mortality was 76% in diabetic patients
versus 13% in those without diabetes (33). Moreover, the
effect of the genetic predisposition score of high blood
pressure on CVD risk was even stronger than our pre-
viously observed effect of the T2D genetic predisposition
score (;3% increased CVD risk per diabetes risk allele) in
the same diabetic populations. Consistently, in the UK
Prospective Diabetes Study, blood pressure control was
found to be more effective than glycemic control at re-
ducing cardiovascular events in patients with T2D (29).
Our current genetic association study lends support to this
notion and also suggests that diabetic patients with
a higher hypertension genetic predisposition score may
need more blood pressure management to reduce CVD
risk, although the optimal blood pressure goal for diabetic
patients remains unknown (35–37).
The major strengths of our study include the consistent
ﬁndings in two independent studies of diabetic patients,
high-quality data of multiple genetic variants, and minimal
population stratiﬁcation (11). Several limitations need to
be acknowledged. Blood pressure levels were not mea-
sured in our study samples; thus, we did not test the as-
sociation between the genetic predisposition score and
blood pressure, but we conﬁrmed the association with
hypertension in patients with T2D. The associations of
these genetic variants with hypertension and blood pres-
sure have been well established in the previous GWAS (5).
Although our genetic predisposition score captured the
combined information from the established genetic var-
iants for blood pressure thus far, it may account for only
FIG. 1. Linear relationship between blood pressure genetic predisposition score and risk of CVD. Data are OR (solid lines) and 95% CI (dashed
lines), adjusted for age, BMI, family history of myocardial infarction, smoking, menopausal status (women only), physical activity, alcohol intake,
DASH diet score, nonnarcotic analgesics use, and supplemental folic acid use.
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a small amount of variation of blood pressure (5). Because
of the relative small number of stroke case subjects, we
did not perform the association analysis for stroke risk
separately. However, we observed similar genetic effect on
risk of CVD (stroke and CHD) and CHD. The previously
reported results for risk of stroke and coronary artery
disease were also similar in the general populations (5). In
addition, our study only includes diabetic patients of
European ancestry, and it remains to be examined whether
the results are generalizable to other ethnic groups.
In conclusion, we found that the genetic predisposition
to high blood pressure was signiﬁcantly associated with an
increased risk of cardiovascular complications among men
and women with T2D, independent of dietary and lifestyle
risk factors. The observed genetic association in diabetic
patients was stronger than that in the general populations.
These results improve our understanding of the genetic
predisposition to high blood pressure and risk of CVD and
also support the causal role of high blood pressure in the
development of CVD. Treatment of high blood pressure is
important and needs to be a therapeutic priority in patients
with T2D, particularly in those with a high genetic risk.
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